H3.3-K27M Neoantigen Vaccine (TCRCure Biopharma)

N/A

Report date: 2025/06/07 20:00:15

Base Information

Drug NameH3.3-K27M Neoantigen Vaccine (TCRCure Biopharma)
Drug Alias Namehistone H3.3-K27M targeted neoantigen vaccine therapy (diffuse intrinsic pontine gliomas) （TCRCure Biopharma）
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsDiffuse Intrinsic Pontine Glioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTcrcure Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsDiffuse Intrinsic Pontine Glioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A